

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

March 18, 2024

To Shareholders,

Company Name: Renascience Inc.

Representative: Koji Naito, President & CEO

(Code: 4889 TSE Growth)

For inquiries, please contact Administration Dept.

**Notice of Publication of Article Related to the Company's**  
**Software as a Medical Device in Nature**

The Company has been developing the software as a medical device (SaMD) to help diabetes insulin therapy, and the other SaMD to support maintenance hemodialysis treatment, in collaboration with several universities including Tohoku University, NEC Corporation, and NEC Solution Innovators, Ltd (NES).

The March 14 issue of Nature, an international, comprehensive scientific journal (printed and online edition), published an article publicizing the Company's SaMD as "A HOTSPOT FOR RESEARCH AND DEVELOPMENT OF MEDICAL AI" (a part of Nature Index Health Sciences).

Article ad URL: <https://www.nature.com/articles/d42473-023-00376-2>

End